Delphi advisor to ProstaLund in connection with rights issue

Delphi has assisted ProstaLund AB (publ) in connection with a rights issue that provides ProstaLund with approximately 23 MSEK before issuance costs.

ProstaLund is a Swedish medical technology company. The company develops innovative products and treatments in the field of urology. ProstaLund is listed on the Nasdaq First North Growth Market and has approximately 4,000 shareholders.

Delphi’s team consisted of Micael Karlsson, Ludvig Borg and Elfie Ekegren Franzetti.